KTTA
NASDAQPasithea Therapeutics Corp.
Price$0.59+0.01 (+1.26%)
05:30 PM07:30 PM
News · 26 weeks31-92%
2025-12-142026-06-07
Mix1890d
- Insider9(50%)
- Other5(28%)
- SEC Filings3(17%)
- Leadership1(6%)
Latest news
25 items- PRPasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)MIAMI, June 02, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to PAS-004 for the treatment of Amyotrophic Lateral Sclerosis (ALS). "ALS remains a devastating neurodegenerative disease with limited treatment options and significant unmet medical need," said Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea. "This designation further supports our efforts to explore the potential of PAS-004 in ALS and other serious diseases where
- SECSEC Form 10-Q filed by Pasithea Therapeutics Corp.10-Q - Pasithea Therapeutics Corp. (0001841330) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Pasithea Therapeutics Corp.SCHEDULE 13G/A - Pasithea Therapeutics Corp. (0001841330) (Subject)
- INSIDERSEC Form 4 filed by Chief Executive Officer Marques Tiago4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)
- INSIDERSEC Form 4 filed by Director Dumesnil Simon4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)
- INSIDERSEC Form 4 filed by Director Steinman Lawrence4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Schneiderman Daniel H4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Krishnan Kartik4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)
- INSIDERSEC Form 4 filed by Director Leahy Emer4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)
- INSIDERSEC Form 4 filed by Director Novak Alfred J4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)
- INSIDERSEC Form 3 filed by new insider Krishnan Kartik3 - Pasithea Therapeutics Corp. (0001841330) (Issuer)
- SECPasithea Therapeutics Corp. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Pasithea Therapeutics Corp. (0001841330) (Filer)
- PRPasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical OfficerMIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced the appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer (CMO) of the Company, effective May 1, 2026. Dr. Krishnan will oversee all clinical development and medical strategy as the Company advances PAS-004 through the clinic for the treatment of neurofibromatosis type 1 (NF1) associated plexiform and cutaneous neurofibromas. "We are delighted to welcome Dr. Krishnan, who is recognized for his strategic approach to clinical development and commi
- PRPasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)MIAMI, April 20, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to PAS-004 for treatment of Neurofibromatosis type-1 (NF1). The FDA grants RPDD for serious or life-threatening diseases in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years and affect fewer than 200,000 people in the U.S. There are approximately 115,000 individuals in the U.S living with NF1. Under the
- INSIDERSEC Form 3 filed by new insider Coastlands Capital Lp3 - Pasithea Therapeutics Corp. (0001841330) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Pasithea Therapeutics Corp.SCHEDULE 13G - Pasithea Therapeutics Corp. (0001841330) (Subject)
- PRPasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant MorbidityMIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PAS-004 for the treatment of NF1-associated PN causing significant morbidity. "We appreciate the FDA's decision that PAS-004 meets the criteria for Fast Track designation for this indication," said Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea. "The ability to have early and frequent interactions with the FDA supports our goal to expeditiously develop PAS-004
- SECSEC Form 10-K filed by Pasithea Therapeutics Corp.10-K - Pasithea Therapeutics Corp. (0001841330) (Filer)
- SECPasithea Therapeutics Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Pasithea Therapeutics Corp. (0001841330) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Pasithea Therapeutics Corp.SCHEDULE 13G/A - Pasithea Therapeutics Corp. (0001841330) (Subject)
- SECSEC Form SCHEDULE 13G filed by Pasithea Therapeutics Corp.SCHEDULE 13G - Pasithea Therapeutics Corp. (0001841330) (Subject)
- PRPasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference– Virtual presentation scheduled for Thursday, February 26, 2026, at 4:00 PM ET –– Webcast may be accessed here – MIAMI, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of NF1-associated plexiform neurofibromas (NF1-PN), today announced that Chief Executive Officer Tiago Reis Marques will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format February 25–26, 2026. The Company's presentation is scheduled for Thursday, Feb 26 at 4:00-4:30 PM ET in Track 2,
- SECSEC Form SCHEDULE 13G filed by Pasithea Therapeutics Corp.SCHEDULE 13G - Pasithea Therapeutics Corp. (0001841330) (Subject)
- SECSEC Form S-8 filed by Pasithea Therapeutics Corp.S-8 - Pasithea Therapeutics Corp. (0001841330) (Filer)
- SECPasithea Therapeutics Corp. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Pasithea Therapeutics Corp. (0001841330) (Filer)
KTTA FAQ
6 questionsWhere does KTTA stock trade?
Pasithea Therapeutics Corp. (KTTA) is listed on NASDAQ.What sector and industry is KTTA in?
Pasithea Therapeutics Corp. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Pasithea Therapeutics Corp. go public?
Pasithea Therapeutics Corp. (KTTA) completed its IPO in 2021.What are analysts saying about KTTA?
Pasithea Therapeutics Corp. has had 1 recent analyst action on file. The most recent action was from EF Hutton: Buy with a $325.00 price target on 2021-12-14. Recent price targets cluster around $325.00.What companies are similar to KTTA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare KTTA side-by-side with any of them on Quantisnow.How can I track KTTA on Quantisnow?
Quantisnow aggregates Pasithea Therapeutics Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KTTA to receive live email and push alerts on every new disclosure.